TAG symposium “Cascades: Improving TB Care” - presentations now available online
Second in a series of symposia calling for Zero TB Deaths, New Infections, and Suffering.
The Treatment Action Group (TAG) “Cascades: Improving TB Care” symposium was held November 1 at the 2013 International Union World Conference on Lung Health in Paris, France. Co-sponsored by TAG, Médecins Sans Frontières (MSF), Partners In Health (PIH), the Harvard Medical School Department of Global Health and Social Medicine, and the Stop TB Partnership (STBP), it was the second in a series of symposia calling for Zero TB Deaths, New Infections, and Suffering. TAG’s TB/HIV Project Director, Colleen Daniels introduced the symposium comprised of three panels on key topic areas including: cascades for patient retention and cure; interventions and solutions; and drug supply, demand, and procurement. By clicking the following links you will be able to access the presentation slides for each speaker.
Welcome
Colleen Daniels, TAG
[Link to Slides]
Panel 1 – Cascades for patient retention and cure, what do we need?
Moderated by Lucica Ditiu, STBP
Three Epiphanies
Paul Farmer, Harvard Medical School & PIH
[Link to Slides]
Learning from the HIV experience: Continuum of Care Initiative
Ken Castro, U.S. Centers for Disease Control and Prevention
[Link to Slides]
Adapting TB and HIV responses to achieve zero: The South African experience
Yogan Pillay, Deputy Director General, National Department of Health, South Africa
NO SLIDES
Panel 2 -- Interventions and solutions
Moderated by Richard Chaisson, Johns Hopkins University
Can zero TB deaths become a reality? Lessons from Tomsk, Russian Federation
Salmaan Keshavjee, Harvard Medical School & PIH
[Link to Slides]
Know your epidemic
David Dowdy, Johns Hopkins University
[Link to Slides]
Patient centered approaches to cure
Jigna Rao, Patient Advocate
[Link to Testimony]
Panel 3 – Drug supply, demand and procurement
Moderated by Mark Harrington, TAG
Global TB drug market
Joel Keravec, Global Drug Facility
NO SLIDES
New Drugs, New Regimens, New Opportunities for MDR-TB
Jen Cohn, MSF
[Link to Slides]
